Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

K-Dur, Klor-Con, Slow-K, Micro-K, K-Lyte/Cl (1)

[[:Category:Electrolyte_replacements|Electrolyte replacement]] (1) · [[:Category:Potassium_supplements|Potassium supplement]] (1)

None (1)

'"`UNIQ--vote-000002EE-QINU`"', '"`UNIQ--vote-000002EF-QINU`"' (1)

10-20 mEq PO daily for prevention; treat established hypokalemia per measured deficit, typically 40-100 mEq/d in divided doses; IV 10 mEq/h peripheral, 20 mEq/h central with telemetry (1)

8, 10, 20, 25 mEq tablets/capsules (most ER); effervescent and oral solution; IV concentrate (must be diluted) (1)

IV peripheral 10 mEq/h (40 mEq/L); IV central 20 mEq/h with cardiac monitoring; PO single doses generally ≤40 mEq (1)

IV (1) · Oral (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

Variable; depends on ongoing losses (1)

Not meaningfully described for an electrolyte; distribution between intra- and extracellular compartments is the relevant kinetic (1)

60-80% (oral) (1)

Generally safe at replacement doses; treat the underlying cause of hypokalemia.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

[[USLegal:Prescription only|Rx-only]] (higher concentrations and IV) and OTC (low-dose supplements) in US (1)